Skip to main content

Table 1 Participant characteristics

From: Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials

Demographics

Normal subjects (n=24)

Heart failure subjects (n=25)

Age

28.6 ± 5.9

62.7 ± 14.3

Male

8 (33.3)

12 (48.0)

Hematocrit (%)

39.7 ± 3.8

40.5 ± 3.1

Serum creatinine (mg/dL)

0.75 ± 0.15

0.91 ± 0.28

eGFR (ml/min)

115.5 ± 21.5

82.3 ± 18.5

Medical history

  

Diabetes Mellitus(%)

0 (0)

2 (8.0)

Smoking

3 (12.5)

1 (4.0)

Hypertension

0 (0)

14 (56.0)

Hyperlipidemia

0 (0)

8 (40.0)

LV function by CMR

  

EDV (ml)

147.6 ± 31.8

214.8 ± 116.5

ESV (ml)

56.5 ± 14.9

133.9 ± 104.5

EF (%)

61.9 ± 4.0

42.1 ± 18.7

Mass (g)

111.0 ± 36.6

203.0 ± 110.6

Stroke volume (ml)

91.1 ± 19.4

81.0 ± 43.7

  1. Note: Mean and standard deviation or number and percentage as appropriate. LV, left ventricular; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction.